DK1750716T3 - Behandling af T-celle-lymfom under anvendelse af 10-propargyl-10-deazaaminopterin - Google Patents

Behandling af T-celle-lymfom under anvendelse af 10-propargyl-10-deazaaminopterin

Info

Publication number: DK1750716T3
Authority: DK; Denmark
Prior art keywords: cell lymphoma; deazaaminopterin; propargyl; treatment; amount
Prior art date: 2004-05-30

Application number

DK05756183T

Other languages

Danish (da)

English (en)

Inventor

Owen A O'connor

Francis Sirotnak

Original Assignee

Sloan Kettering Inst Cancer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-05-30

Filing date

2005-05-31

Publication date

2008-12-08

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34971703&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1750716(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-05-31 Application filed by Sloan Kettering Inst Cancer filed Critical Sloan Kettering Inst Cancer

2008-12-08 Application granted granted Critical

2008-12-08 Publication of DK1750716T3 publication Critical patent/DK1750716T3/da

Links

206010042971 T-cell lymphoma Diseases 0.000 title abstract 4
208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 title abstract 4
OGSBUKJUDHAQEA-WMCAAGNKSA-N pralatrexate Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CC(CC#C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OGSBUKJUDHAQEA-WMCAAGNKSA-N 0.000 title abstract 3
239000003814 drug Substances 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
230000003442 weekly effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

DK05756183T 2004-05-30 2005-05-31 Behandling af T-celle-lymfom under anvendelse af 10-propargyl-10-deazaaminopterin DK1750716T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US52159304P	2004-05-30	2004-05-30
PCT/US2005/019169 WO2005117891A1 (fr)	2004-05-30	2005-05-31	Traitement du lymphome t utilisant 10-propargyl-10-deazaaminopterine

Publications (1)

Publication Number	Publication Date
DK1750716T3 true DK1750716T3 (da)	2008-12-08

Family

ID=34971703

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK05756183T DK1750716T3 (da)	2004-05-30	2005-05-31	Behandling af T-celle-lymfom under anvendelse af 10-propargyl-10-deazaaminopterin

Country Status (23)

Country	Link
US (4)	US7939530B2 (fr)
EP (1)	EP1750716B1 (fr)
JP (1)	JP5005532B2 (fr)
KR (1)	KR101189693B1 (fr)
CN (2)	CN102824346B (fr)
AT (1)	ATE405272T1 (fr)
AU (1)	AU2005249516B2 (fr)
BR (1)	BRPI0510895A (fr)
CA (1)	CA2565968C (fr)
DE (1)	DE602005009176D1 (fr)
DK (1)	DK1750716T3 (fr)
ES (1)	ES2313365T3 (fr)
HR (1)	HRP20080569T3 (fr)
ME (1)	ME01087B (fr)
MX (1)	MXPA06013559A (fr)
NO (1)	NO337276B1 (fr)
NZ (2)	NZ551082A (fr)
PL (1)	PL1750716T3 (fr)
PT (1)	PT1750716E (fr)
RS (1)	RS50622B (fr)
SI (1)	SI1750716T1 (fr)
WO (2)	WO2005117891A1 (fr)
ZA (1)	ZA200609266B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6835750B1 (en)	2000-05-01	2004-12-28	Accera, Inc.	Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
US8263354B2 (en)	2004-05-30	2012-09-11	Sloan-Kettering Institute For Cancer Research	Methods for assessing cancer for increased sensitivity to 10-propargyl-10-deazaaminopterin
US20080188479A1 (en)	2004-05-30	2008-08-07	Sloan-Kettering Institute For Cancer Research	Methods to Treat Cancer with 10-propargyl-10-deazaaminopterin and Methods for Assessing Cancer for Increased Sensitivity to 10-propargyl-10-deazaaminopterin
ZA200609266B (en) *	2004-05-30	2008-12-31	Sloan Kettering Inst Cancer	Treatment of t-cell lymphoma using 10-propargyl-10-deaza-aminopterin
CA2853992C (fr)	2007-07-31	2020-06-23	Cerecin Inc.	Utilisation d'essais genomiques et de composes cetogeniques pour le traitement d'une fonction cognitive reduite
US20100248249A1 (en) *	2007-08-17	2010-09-30	Allos Therapeutics, Inc.	Methods for Assessing Cancer for Increased Sensitivity to 10-Propargyl-10-Deazaaminopterin by Assessing Egfr Levels
WO2009026234A1 (fr) *	2007-08-17	2009-02-26	Allos Therapeutics, Inc.	Association de 10-propargyl-10-déazaaminoptérine et d'erlotinib pour le traitement du cancer des poumons non à petites cellules
US9901578B2 (en)	2007-08-17	2018-02-27	Allos Therapeutics, Inc.	Combination of 10-propargyl-10-deazaaminopterin and erlotinib for the treatment of non-small cell lung cancer
AU2009266869B2 (en)	2008-07-03	2016-07-07	Cerecin Inc.	Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders
WO2010022277A2 (fr) *	2008-08-20	2010-02-25	O'connor Owen A	Association de 10-propargyl-10-déazaaminoptérine et de bortézomib pour le traitement de cancers
KR101743426B1 (ko) *	2010-02-02	2017-06-15	알로스 쎄러퓨틱스, 아이엔씨.	10-프로파길-10-데아자아미노프테린의 광학적으로 순수한 부분입체이성질체 및 이의 용도
ES2541689T3 (es) *	2010-06-02	2015-07-23	Allos Therapeutics, Inc.	Métodos para tratar trastornos resistentes a metotrexato con 10-propargil-2-desazaaminopterina
US20130178441A1 (en) *	2010-08-10	2013-07-11	Allos Therapeutics, Inc.	Methods for Extending Progression-Free Survival using 10-Propargyl-10-Deazaaminopterin
WO2013164856A1 (fr)	2012-05-04	2013-11-07	Avra Laboratories Private Limited	Procédé pour la préparation d'intermédiaires de synthèse de 10-propargyl-10-déazaaminoptérine (pralatrexate) et ses intermédiaires
CN103274943B (zh) *	2013-05-24	2015-01-21	苏州明锐医药科技有限公司	4-[1-(2-丙炔基)-3,4-二氧代正丁基]苯甲酸酯及其制备方法
WO2016205203A1 (fr)	2015-06-16	2016-12-22	Spectrum Pharmaceuticals, Inc.	Thérapie combinée utilisant du belinostat et du pralatrexate pour le traitement des lymphomes

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4393064A (en)	1976-03-05	1983-07-12	Sri International	Process and composition for treatment of leukemia and process for preparing the same
US4652533A (en)	1983-04-28	1987-03-24	Pandex Laboratories, Inc.	Method of solid phase immunoassay incorporating a luminescent label
US4843155A (en)	1987-11-19	1989-06-27	Piotr Chomczynski	Product and process for isolating RNA
DE69121844T2 (de)	1990-11-20	1997-01-23	Behringwerke Ag	Immunotest für Cyclosporin
US5354751A (en) *	1992-03-03	1994-10-11	Sri International	Heteroaroyl 10-deazaamino-pterine compounds and use for rheumatoid arthritis
US5981592A (en) *	1995-03-13	1999-11-09	Loma Linda University Medical Center	Method and composition for treating cystic fibrosis
US6323205B1 (en) *	1996-07-17	2001-11-27	Sloan-Kettering Institute For Cancer Research	Combinations of 10-propargyl-10-deazaaminopterin and taxols and methods of using same in the treatment of tumors
WO1998002163A1 (fr) *	1996-07-17	1998-01-22	Sloan-Kettering Institute For Cancer Research	Compositions purifiees de 10-propargyl-10-deazaaminopterine et leur methodes d'utilisation pour le traitement de tumeurs
GB0128510D0 (en) *	2001-11-28	2002-01-23	Novartis Ag	Organic compounds
ZA200609266B (en)	2004-05-30	2008-12-31	Sloan Kettering Inst Cancer	Treatment of t-cell lymphoma using 10-propargyl-10-deaza-aminopterin

2005
- 2005-05-31 ZA ZA200609266A patent/ZA200609266B/xx unknown
- 2005-05-31 BR BRPI0510895-0A patent/BRPI0510895A/pt not_active Application Discontinuation
- 2005-05-31 RS RSP-2008/0470A patent/RS50622B/sr unknown
- 2005-05-31 DE DE602005009176T patent/DE602005009176D1/de not_active Expired - Lifetime
- 2005-05-31 EP EP05756183A patent/EP1750716B1/fr not_active Expired - Lifetime
- 2005-05-31 CN CN201210342831.8A patent/CN102824346B/zh not_active Expired - Lifetime
- 2005-05-31 MX MXPA06013559A patent/MXPA06013559A/es active IP Right Grant
- 2005-05-31 HR HR20080569T patent/HRP20080569T3/xx unknown
- 2005-05-31 CN CNA2005800173160A patent/CN1960734A/zh active Pending
- 2005-05-31 CA CA2565968A patent/CA2565968C/fr not_active Expired - Lifetime
- 2005-05-31 SI SI200530392T patent/SI1750716T1/sl unknown
- 2005-05-31 AU AU2005249516A patent/AU2005249516B2/en not_active Expired
- 2005-05-31 PT PT05756183T patent/PT1750716E/pt unknown
- 2005-05-31 NZ NZ551082A patent/NZ551082A/en not_active IP Right Cessation
- 2005-05-31 WO PCT/US2005/019169 patent/WO2005117891A1/fr not_active Ceased
- 2005-05-31 AT AT05756183T patent/ATE405272T1/de active
- 2005-05-31 NZ NZ576849A patent/NZ576849A/en not_active IP Right Cessation
- 2005-05-31 DK DK05756183T patent/DK1750716T3/da active
- 2005-05-31 PL PL05756183T patent/PL1750716T3/pl unknown
- 2005-05-31 US US11/568,254 patent/US7939530B2/en active Active
- 2005-05-31 JP JP2007515512A patent/JP5005532B2/ja not_active Expired - Lifetime
- 2005-05-31 WO PCT/US2005/019170 patent/WO2005117892A1/fr not_active Ceased
- 2005-05-31 KR KR1020117012373A patent/KR101189693B1/ko not_active Expired - Lifetime
- 2005-05-31 ME MEP-2008-310A patent/ME01087B/fr unknown
- 2005-05-31 US US11/141,868 patent/US7622470B2/en not_active Expired - Lifetime
- 2005-05-31 ES ES05756183T patent/ES2313365T3/es not_active Expired - Lifetime
2006
- 2006-12-22 NO NO20065971A patent/NO337276B1/no unknown
2009
- 2009-10-21 US US12/603,117 patent/US8299078B2/en not_active Expired - Lifetime
2012
- 2012-10-29 US US13/663,234 patent/US20130053391A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CN1960734A (zh)	2007-05-09
BRPI0510895A (pt)	2007-11-27
ME01087B (fr)	2012-12-20
WO2005117891A1 (fr)	2005-12-15
JP2008501038A (ja)	2008-01-17
JP5005532B2 (ja)	2012-08-22
US20130053391A1 (en)	2013-02-28
AU2005249516A1 (en)	2005-12-15
NO337276B1 (no)	2016-02-29
HRP20080569T3 (en)	2008-12-31
US7939530B2 (en)	2011-05-10
CN102824346B (zh)	2015-04-22
CA2565968C (fr)	2013-01-08
US20050267117A1 (en)	2005-12-01
KR101189693B1 (ko)	2012-10-10
RS50622B (sr)	2010-06-30
AU2005249516B2 (en)	2010-11-18
US7622470B2 (en)	2009-11-24
ATE405272T1 (de)	2008-09-15
MXPA06013559A (es)	2007-04-24
SI1750716T1 (sl)	2009-06-30
EP1750716A1 (fr)	2007-02-14
ZA200609266B (en)	2008-12-31
US20080058280A1 (en)	2008-03-06
US20100120777A1 (en)	2010-05-13
NO20065971L (no)	2006-12-22
DE602005009176D1 (de)	2008-10-02
US8299078B2 (en)	2012-10-30
CA2565968A1 (fr)	2005-12-15
ES2313365T3 (es)	2009-03-01
HK1177901A1 (en)	2013-08-30
PT1750716E (pt)	2008-11-04
KR20110081327A (ko)	2011-07-13
EP1750716B1 (fr)	2008-08-20
PL1750716T3 (pl)	2009-01-30
NZ551082A (en)	2009-06-26
NZ576849A (en)	2011-03-31
CN102824346A (zh)	2012-12-19
WO2005117892A1 (fr)	2005-12-15

Publication	Publication Date	Title
DK1750716T3 (da)	2008-12-08	Behandling af T-celle-lymfom under anvendelse af 10-propargyl-10-deazaaminopterin
NO20014519L (no)	2001-10-25	Apomorfin- og sildenafilpreparat
WO2004062604A3 (fr)	2005-05-26	Traitement du cancer par le 2-desoxyglucose
CA2683786C (fr)	2021-10-26	Utilisation du tapentadol dans le traitement de la douleur et avec une incidence reduite d'effets secondaires induits par le tapentadol
RU2013148721A (ru)	2015-05-10	Комбинации соединений, ингибирующих акт и вемурафениба и способы их применения
CY1108217T1 (el)	2014-02-12	Μεθοδος χορηγησης βουπρενορφινης για τη θεραπεια της καταθλιψης
NO20072931L (no)	2007-08-03	Forbedret doseringsregime av temozolomid for behandling av kreft basert pa pasientens MGMT-niva
RU2013123646A (ru)	2014-12-10	Комбинированная композиция
NZ591525A (en)	2014-03-28	Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
JP2002523370A5 (fr)	2006-08-17
MX2009003532A (es)	2009-06-26	Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
IS2630B (is)	2010-06-15	Meðferð á fráhvarfseinkennum
DK1689404T3 (da)	2009-01-26	Kombination af et-743 med 5-fluoracil-prodrugs til behandling af cancer
DE60222383D1 (de)	2007-10-25	Medikament zur verabreichung von amifostin und verwandten wirkstoffen
AR023185A1 (es)	2002-09-04	Tratamiento de cancer mejorado con temozolomida
RU2009101026A (ru)	2010-07-20	Применение тимозина-альфа-1 для получения лекарственного средства для лечения злокачественной меланомы на iv стадии
WO2001080895A3 (fr)	2002-08-08	Procedes et compositions pour le traitement de troubles cardiaques
AR029160A1 (es)	2003-06-18	El uso del interferon-alfa pegilado para la preparacion de un medicamento para el tratamiento del carcinoma de celula renal, un kit y el uso del mismo
MX2010006310A (es)	2010-08-31	O-desmetil-venlafaxina para el tratamiento de transtorno depresivo mayor.
MX2012005497A (es)	2012-07-03	Tivozanib y temsirolimus en combinacion.
WO2006124573A3 (fr)	2007-02-08	Traitement du cancer a l'aide de 2-desoxyglucose
WO2008079818A3 (fr)	2008-09-12	Administration intraveineuse de formulations analgésiques hydrosolubles
WO2007093519A3 (fr)	2007-11-01	Nouveau regime d'ibandronate
RU2005114664A (ru)	2006-11-20	Способ лечения хронического панкреатита
RU2007132181A (ru)	2009-03-10	ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ